Home › Funds › Stonepine Capital Management, LLC › ACET
Stonepine Capital Management, LLC position in ACET
ADICET BIO INC · Health Care
Stonepine Capital Management, LLC reported holding 188,201 shares of ACET (ADICET BIO INC) in its Q3 2026 13F filing — a position valued at US$1.3M, representing 1.03% of its reported portfolio and ranking #24 among its reported holdings. Stonepine Capital Management, LLC has disclosed ACET holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Stonepine Capital Management, LLC's ACET position evolved
Stonepine Capital Management, LLC first disclosed a stake in ACET in Q1 2024 at 141,548 shares (US$333K). The position peaked in Q2 2026 at 245,518 shares, worth US$2.1M. Across 9 filings, Stonepine Capital Management, LLC increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 188,201 shares valued at US$1.3M — a reduction of -57,317 shares quarter over quarter.. Notable position changes include a 331% increase in Q2 2024 (shares rose 19% over the following quarter), a 27% trim in Q1 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 141.55K | $332.64K | New |
| Q2 2024 | 609.45K | $737.43K | Add |
| Q3 2024 | 609.45K | $877.60K | Hold |
| Q4 2024 | 700.00K | $673.40K | Add |
| Q1 2025 | 508.27K | $203.50K | Reduce |
| Q4 2025 | 220.01K | $1.85M | New |
| Q1 2026 | 221.96K | $1.51M | Add |
| Q2 2026 | 245.52K | $2.12M | Add |
| Q3 2026 | 188.20K | $1.34M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACET and 13F data
ACET (ADICET BIO INC) is a Health Care company. 24 other funds we track also report a position in ACET — the largest reported positions include Carlyle Group Inc. (US$1.3M), REGENERON PHARMACEUTICALS, INC. (US$432K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACET
- Carlyle Group Inc. 184.29K sh · $1.32M · Q3 2026
- REGENERON PHARMACEUTICALS, INC. 60.51K sh · $432.05K · Q3 2026
More on Stonepine Capital Management, LLC
FAQ
How long has Stonepine Capital Management, LLC held ACET?
Stonepine Capital Management, LLC has disclosed ACET holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is Stonepine Capital Management, LLC's current position in ACET?
As of Q3 2026, Stonepine Capital Management, LLC holds 188.20K shares of ACET (ADICET BIO INC), valued at $1.34M, representing 1.03% of its reported portfolio and ranking #24.
Has Stonepine Capital Management, LLC been buying or selling ACET?
In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC reduced its position in ACET. The position peaked in Q2 2026 at 245.52K shares.
Which other funds hold ACET?
Other major institutional holders of ACET include Carlyle Group Inc., REGENERON PHARMACEUTICALS, INC., among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.